Zomedica Revolutionizes Canine Diagnostics with New Assays

Zomedica, a leading veterinary health company, has recently launched two new quantitative assays on its TRUFORMA(R) platform: Canine NT-proBNP and Progesterone. These innovative tests aim to enhance the speed and accuracy of diagnosing heart disease and pregnancy in dogs, respectively. By offering these assays on the TRUFORMA platform, Zomedica continues to prioritize patient health and practice health, driving better outcomes for pets and pet parents.

Heart disease is a prevalent issue among dogs, with an estimated 10-15% of dogs over 10 years old affected. NT-proBNP, a biomarker for heart failure, is crucial for early detection and monitoring of heart disease in dogs. Zomedica's new Canine NT-proBNP assay provides quantitative results within minutes, enabling veterinarians to make timely treatment decisions. This assay offers significant advantages over traditional methods, which require sending blood samples to reference labs, resulting in delayed results and higher costs.

Pregnancy is also common in dogs, with an estimated 48% of female dogs experiencing at least one pregnancy. Progesterone testing is essential for confirming pregnancy and monitoring hormone levels during gestation. Zomedica's Progesterone assay allows for rapid, in-clinic diagnosis of pregnancy in dogs, replacing the need for expensive and time-consuming ultrasound examinations. Both assays deliver reference lab quality results at the point of care, streamlining workflows and increasing practice profitability.

The global veterinary diagnostics market, valued at $11.5 billion in 2020, is projected to reach $17.2 billion by 2027, growing at a CAGR of 6.5%. The canine diagnostics segment, including NT-proBNP and progesterone testing, is a significant contributor to this growth. With an estimated 75 million dogs in the U.S. alone, the demand for these quantitative assays on the TRUFORMA(R) platform is expected to be high, potentially capturing a substantial market share in this growing segment.

Zomedica's commitment to innovation and improving patient care is evident in these new assays. By offering rapid, accurate results at the point of care, Zomedica is driving demand for its TRUFORMA platform and solidifying its position as a leader in veterinary diagnostics. As the company continues to expand its product portfolio, it is well-positioned to capitalize on the growing market for canine diagnostics and contribute to better health outcomes for dogs worldwide.